Mixed gangliocytoma-pituitary neuroendocrine tumour: clinical, immunohistochemical, and molecular genetic profiles in a series of four patients
Authors:
- Konstantinos DalakasKDKonstantinos Dalakas
- Britt Edén EngströmBEBritt Edén Engström
- Abdellah TebaniATAbdellah Tebani
- Thomas Olsson BontellTBThomas Olsson Bontell
- Alice LarssonALAlice Larsson
- Helena NordHNHelena Nord
- Cecilia LindskogCLCecilia Lindskog
- Fredrik PonténFPFredrik Pontén
- Henning Bünsow BoldtHBHenning Bünsow Boldt
- Oskar RagnarssonOROskar Ragnarsson
- Olivera Casar-BorotaOCOlivera Casar-Borota
Open Access
- 30 January 2026
- journal article
- research article
- Published by Springer Nature in Acta Neuropathologica Communications
- Vol. 14 (1)
Abstract
The vast majority of tumours in the sellar region are pituitary neuroendocrine tumours, also called pituitary adenomas. Sellar gangliocytomas (GCs), benign tumours that originate from neuronal ganglionic cells, account for less than 1% of sellar tumours. Even rarer are mixed gangliocytoma-pituitary neuroendocrine tumours (GC-PitNET). These tumours are often associated with hormone hypersecretion, most commonly resulting in acromegaly. The histogenesis of mixed GC–PitNET is currently unclear. In this paper, we present comprehensive clinical, immunohistochemical, targeting enrichment next generation DNA sequencing, and genome-wide methylation data from four patients with mixed GC-PitNETs, three with acromegaly and one with Cushing’s disease. Transcriptomic data are also included for two of the patients. Our findings indicate that mixed GC-PitNETs have different clinical course, with the acromegaly patients showing greater resistance to pharmacological therapy, as well as different protein expression and molecular features compared to respective pure PitNETs. The transcriptomic data on two patients with somatotroph GC-PitNET show involvement of mitochondrial and ribosomal genes, suggesting a distinct gene expression pattern, in comparison with pure somatotroph tumours. Furthermore, the expression pattern of selected stem cell markers, mainly SOX9, supports a common origin of the neuroendocrine and ganglionic tumour components, suggesting the involvement of stem cells in tumorigenesis.Keywords
Funding Information
- Uppsala University
This publication has 42 references indexed in Scilit:
- Multiple tumorous lesions of the pituitary glandHormones, 2022
- eEF1A1 promotes colorectal cancer progression and predicts poor prognosis of patientsCancer Medicine, 2022
- RPL41 sensitizes retinoblastoma cells to chemotherapeutic drugs via ATF4 degradationJournal of Cellular Physiology, 2020
- Pangenomic Classification of Pituitary Neuroendocrine TumorsCancer Cell, 2020
- Mixed gangliocytoma-pituitary adenoma in the sellar region: a large-scale single-center experienceActa Neurochirurgica, 2018
- Practical implementation of DNA methylation and copy-number-based CNS tumor diagnostics: the Heidelberg experienceActa Neuropathologica, 2018
- Phenotypical and Pharmacological Characterization of Stem-Like Cells in Human Pituitary AdenomasMolecular Neurobiology, 2016
- Ganglion cell containing pituitary adenomas: signs of neuronal differentiation in adenoma cellsActa Neuropathologica, 2006
- Intrasellar gangliocytomas associated with acromegalyBrain Tumor Pathology, 2002
- Hypothalamic neuronal hamartoma associated with pituitary growth hormone cell adenoma and acromegalyActa Neuropathologica, 1980